Yang Lu-Lu, Liu Xin, Li Qing, Zhu Xiao-Yu, Wang Xing-Bing, Zhu Wei-Bo
Department of Hematology, Anhui Provincial Hospital, Hefei 230001,Anhui Province, China.
Department of Hematology, Anhui Provincial Hospital, Hefei 230001,Anhui Province, China. E-mail:
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Feb;22(1):1-5. doi: 10.7534/j.issn.1009-2137.2014.01.001.
This study was aimed to explore the immunophenotyping characteristics of acute myeloid leukemia (AML) and their correlation with the curative efficacy. The bone marrow or blood samples were collected from 516 patients with newly diagnosed AML, and their immunophenotypes were analyzed by flow cytometry. The results showed that (1) In 516 cases, the ratios of myeloid antigen expression were higher, as follows: MPO 95.0%, CD33 93.0%, CD13 88.8%, CD117 69.4%; and the expressions of CD14, CD15, CD64 and CD71 were lower, meanwhile 145 cases were accompanied with lymphocyte antigen expression, the ratios were as follows: CD7 21.5%, CD19 6.0%, CD2 0.78%, CD10 0.58% and CD20 0.58%; the positive expression rate of CD71 in M6 was 100%, and that of CD64 in M5 was the highest (30.2%); the overall positive rate of CD34 was 57.8%. (2) After first chemotherapy, the complete remission (CR) rate was 64.7%, CR rate of CD34(+) patients was lower than that of CD34(-) in M3 group (P = 0.019). The CR rate of CD34(+) patients was significantly lower than that of CD34(-) in non-M3 group (P = 0.002). The CR rate of CD19(+) patients was higher than CD19(-) (P = 0.028); the CR rate of CD7(+) patients was significantly lower than that of CD7(-) (P = 0.002); the CR rate of CD71(+) patients was lower than that of CD71(-) (P = 0.013); the CR rate of MPO(+) patients was higher than that of MPO(-) (P = 0.015). Between the CR rate of CD11b, CD13, CD33-positive and-negative group, the difference was not statistically significant (P > 0.05). It is concluded that the phenotype is a prerequisite for the diagnosis of AML, and can help to guide the clinical typing, selection of treatment protocols and evaluation of prognosis.
本研究旨在探讨急性髓系白血病（AML）的免疫表型特征及其与疗效的相关性。收集516例新诊断AML患者的骨髓或血液样本，采用流式细胞术分析其免疫表型。结果显示：（1）516例中，髓系抗原表达比例较高，依次为：MPO 95.0%、CD33 93.0%、CD13 88.8%、CD117 69.4%；CD14、CD15、CD64及CD71表达较低，同时有145例伴有淋巴细胞抗原表达，比例依次为：CD7 21.5%、CD19 6.0%、CD2 0.78%、CD10 0.58%、CD20 0.58%；M6中CD71阳性表达率为100%，M5中CD64阳性率最高（30.2%）；CD34总体阳性率为57.8%。（2）首次化疗后，完全缓解（CR）率为64.7%，M3组中CD34（+）患者的CR率低于CD34（-）患者（P = 0.019）。非M3组中CD34（+）患者的CR率显著低于CD34（-）患者（P = 0.002）。CD19（+）患者的CR率高于CD19（-）患者（P = 0.028）；CD7（+）患者的CR率显著低于CD7（-）患者（P = 0.002）；CD71（+）患者的CR率低于CD71（-）患者（P = 0.013）；MPO（+）患者的CR率高于MPO（-）患者（P = 0.015）。CD11b、CD13、CD33阳性与阴性组之间的CR率差异无统计学意义（P > 0.05）。结论：免疫表型是AML诊断的前提条件，有助于指导临床分型、治疗方案选择及预后评估。
